Tealwood Asset Management Inc. Sells 16,786 Shares of Corcept Therapeutics Incorporated $CORT

Tealwood Asset Management Inc. trimmed its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 53.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,370 shares of the biotechnology company’s stock after selling 16,786 shares during the period. Tealwood Asset Management Inc.’s holdings in Corcept Therapeutics were worth $500,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Abacus FCF Advisors LLC purchased a new stake in shares of Corcept Therapeutics in the third quarter valued at approximately $3,238,000. JPMorgan Chase & Co. increased its holdings in Corcept Therapeutics by 223.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock worth $70,632,000 after purchasing an additional 587,053 shares during the period. Pacer Advisors Inc. increased its holdings in Corcept Therapeutics by 6,796.7% during the 3rd quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock worth $32,459,000 after purchasing an additional 384,896 shares during the period. Brown Capital Management LLC bought a new stake in Corcept Therapeutics during the 3rd quarter valued at $19,950,000. Finally, Cerity Partners LLC raised its position in Corcept Therapeutics by 21.4% during the 2nd quarter. Cerity Partners LLC now owns 746,593 shares of the biotechnology company’s stock valued at $54,800,000 after purchasing an additional 131,799 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Director G. Leonard Baker Jr. bought 100,000 shares (~$3.3M) at about $33.14 on March 17, a meaningful insider purchase that signals management confidence and can support short‑term demand. Read More.
• Neutral Sentiment: Short‑interest reports for March 19–20 show effectively zero reported short interest (days‑to‑cover ≈ 0), which appears anomalous and likely reflects reporting quirks rather than a genuine absence of short sellers; this creates uncertainty about short‑seller pressure signals.
• Negative Sentiment: Multiple shareholder‑rights firms (Hagens Berman, Schall, DJS, Pomerantz, Rosen, Glancy, others) have issued class‑action/lead‑plaintiff notices tied to alleged FDA issues and a federal court patent loss — a concentrated legal PR wave that raises litigation risk, could increase future liabilities, and likely weighs on investor confidence. Read More. Read More.
• Negative Sentiment: Zacks Research sharply cut EPS forecasts across 2026–2027 and maintains a “Strong Sell” stance — analyst downgrades and lower near‑term earnings expectations increase downside pressure on valuation and can amplify selling if guidance or legal exposure worsens. Read More.

Insider Buying and Selling

In other news, Director G Leonard Baker, Jr. bought 100,000 shares of the stock in a transaction on Tuesday, March 17th. The stock was bought at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the completion of the purchase, the director directly owned 1,146,631 shares in the company, valued at approximately $37,999,351.34. The trade was a 9.55% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William Guyer sold 8,233 shares of Corcept Therapeutics stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $35.99, for a total transaction of $296,305.67. Following the completion of the transaction, the insider directly owned 2,231 shares in the company, valued at $80,293.69. This represents a 78.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 48,233 shares of company stock valued at $1,817,306 in the last three months. 20.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CORT shares. Canaccord Genuity Group increased their price target on Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, January 23rd. Truist Financial set a $50.00 price objective on Corcept Therapeutics in a report on Wednesday, December 31st. UBS Group began coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective for the company. HC Wainwright dropped their target price on shares of Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Finally, Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price on the stock. in a research report on Wednesday, December 31st. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Corcept Therapeutics has a consensus rating of “Hold” and a consensus target price of $77.17.

Corcept Therapeutics Stock Performance

Shares of Corcept Therapeutics stock opened at $34.64 on Friday. The company has a market capitalization of $3.68 billion, a PE ratio of 42.24 and a beta of 0.29. The company has a 50-day simple moving average of $37.46 and a two-hundred day simple moving average of $61.87. Corcept Therapeutics Incorporated has a one year low of $28.66 and a one year high of $117.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. During the same quarter in the prior year, the business posted $0.26 earnings per share. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. Research analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Corcept Therapeutics Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.